| Literature DB >> 28264433 |
Melanie McGrice1,2, Judi Porter3,4.
Abstract
(1) Background: Medical interventions including assisted reproductive technologies have improved fertility outcomes for many sub-fertile couples. Increasing research interest has investigated the effect of low carbohydrate diets, with or without energy restriction. We aimed to systematically review the published literature to determine the extent to which low carbohydrate diets can affect fertility outcomes; (2)Entities:
Keywords: infertile; ketogenic; low carbohydrate; obese; overweight; polycystic ovarian syndrome; systematic review
Mesh:
Substances:
Year: 2017 PMID: 28264433 PMCID: PMC5372867 DOI: 10.3390/nu9030204
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study selection process.
Studies of low carbohydrate diets in overweight and obese women measuring fertility hormones and other reproductive outcomes.
| Author, Year, Location | Participants; Study Duration | Cause of Infertility | Study Design | Intervention | Comparators | Fertility Outcomes (Pregnancy Rate/Other) |
|---|---|---|---|---|---|---|
| Mavropoulos et al. 2005, USA [ | 11 women with PCOS and BMI >27 from the community; 24 weeks | PCOS | Two arm pre/post study | <20 g carbohydrate/day, ad libitum MJ/day (<6% carbohydrate if consuming 5 MJ/day) | Own control on usual diet (pre-intervention) | Reproductive hormones; Pregnancy rates |
| Moran et al. 2003, Australia [ | 45 overweight women with PCOS; 12 weeks | PCOS | Matched control trial | High protein, low carbohydrate (6 MJ—40% carbohydrate, 30% protein, 30% fat) | Usual diet (55% carbohydrate, 15% protein, 30% fat) but limited to 6 MJ/day | Reproductive hormones; Ovulation rates |
| Palomba et al. 2008, Italy [ | 20 obese PCOS patients with anovulatory infertility; 24 weeks | PCOS | Two arm pre/post study | High protein, low carbohydrate diet (35% protein, 45% carbohydrate, 20% fat) with 3.3 MJ deficit | Usual diet and 3 physical activity sessions per week | Reproductive hormones; Ovulation rates; Pregnancy rates |
| Palomba et al. 2010, Italy [ | 96 overweight or obese Clomiphene citrate resistant women; 2 weeks intervention, 4 weeks clomid (±intervention) | PCOS | Three arm randomised parallel controlled trial | Structured exercise + 35% protein, 45% carbohydrate, 20% fat diet with 4.2 MJ/day deficit + clomiphene citrate | Usual diet followed by clomiphene citrate | Reproductive hormones; Ovulation rate |
| Sim et al. 2014, Australia [ | 49 obese women planning ART; 12 weeks intervention, 12 month follow up | Mixed | Randomised controlled trial | Very low energy diet (2.5 MJ/day, 34% carbohydrate) for 6/52 followed by 6/52 hypocaloric diet | Usual diet | Pregnancy rates |
| Stamets et al. 2004, USA [ | 35 obese women with PCOS; 1 month | PCOS | Randomised controlled trial | Diet (40% carbohydrate, 30% protein, 30% fat with 4.2 MJ/day energy deficit) | Usual diet (55% carbohydrate, 15% protein, 30% fat) with a 4.2 MJ/day energy deficit | Reproductive hormones |
| Thomson et al. 2008, Australia [ | 94 overweight and obese women; 20 weeks | PCOS | Randomised parallel study (only one arm, “Diet Only“ was included in this review) | Diet (5–6 MJ/day, 30% protein, 40% carbohydrate, 30% fat) | Own control on usual diet (pre-intervention) | Reproductive hormones; Ovulation rates |
MJ/day = megajoules per day, PCOS = polycystic ovarian syndrome, BMI = body mass index, ART = assisted reproductive therapy.
Quality assessment of included studies a.
| Author | Validity Rating b | Overall Rating | Examples of Reasons for Downgrading | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||
| Mavropoulos et al. 2005, USA [ | Y | Y | N/A | Y | N/A | Y | Y | Y | Y | N | Neutral | Statement of the role of funding source not included. |
| Moran et al. 2003, Australia [ | Y | Y | Y | Y | N | Y | Y | Y | Y | N | Positive | Statement of the role of funding source not included. |
| Palomba et al. 2008, Italy [ | Y | Y | Y | N | N | Y | Y | Y | Y | Y | Positive | Patients self-selected their intervention groups. Dropout rates were reported, but no further explanation was provided. |
| Palomba et al. 2010, Italy [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Positive | Source of participants (e.g., whether consecutive) was unclear. |
| Sim et al. 2014, Australia [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Positive | Two groups didn’t match all aspects of demographics/anthropometry explained by the strict randomisation technique used. Statement of the role of funding source not included. |
| Stamets et al. 2004, USA [ | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Positive | No reporting of blinding throughout the study protocol. |
| Thomson et al. 2008, Australia [ | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Positive | Unclear whether the study dietitian was blinded. |
Y = response of “yes” to the validity question; N = response of “no” to the validity question; N/A = not applicable. a Assessed using The Quality Criteria Checklist for Primary Research [17]; b Validity items: [1] research question stated; [2] subject selection free from bias; [3] comparable study groups; [4] method for withdrawals described; [5] blinding used; [6] interventions described; [7] outcomes stated, measurements valid and reliable; [8] appropriate statistical analysis; [9] appropriate conclusions, limitations described; [10] funding and sponsorship free from bias. Validity items 2, 3, 6, 7 must be satisfied for a positive quality rating.
Fertility outcomes of included studies.
| Study (Author, Year) | Intervention Group | Control Group | |
|---|---|---|---|
| Reproductive hormones | |||
| Mavropoulos, 2005 [ | Free testosterone ng/dL 1.7 | Free testosterone ng/dL 2.19 | 0.04 |
| Luteinizing Hormone/Follicle Stimulating Hormone ratio 1.21 | Luteinizing Hormone/Follicle Stimulating Hormone ratio 2.23 | 0.03 | |
| Fasting serum insulin mcIU/mL 8.2 | Fasting serum insulin mcIU/mL 23.5 | 0.002 | |
| Moran, 2003 [ | Fasting glucose (mmol/L) 5.42 ± 0.13 | Fasting glucose (mmol/L) 5.31 ± 0.17 | NS |
| Fasting insulin (mU/L) 16.6 ± 2.4 | Fasting insulin (mU/L) 12.8 ± 2.0 | <0.01 | |
| Sex Hormone Binding Globule (nmol/L) 25 ± 2.5 | Sex Hormone Binding Globule (nmol/L) 35 ± 5 | 0.027 | |
| Testosterone (nmol/L) 1.45 ± 0.2 | Testosterone (nmol/L) 1.3 ± 0.1 | 0.01 | |
| Free Androgen Index (nmol/L) 7 ± 1.5 | Free Androgen Index (nmol/L) 4.5 ± 1 | 0.004 | |
| Palomba, 2008 [ | Follicle Stimulating Hormone (mIU/mL) 4.2 ± 13.2 | Follicle Stimulating Hormone (mIU/mL) −1.2 ± 3.2 | NS |
| Testosterone (nmol/L) −28.7 ± 11.7 | Testosterone (nmol/L) −33.4 ± 14.3 | <0.05 | |
| Sex Hormone Binding Globule (nmol/L) 41.9 ± 19.1 | Sex Hormone Binding Globule (nmol/L) 82.5 ± 30.6 | <0.05 | |
| Free Androgen Index (%) −18.1 ± 9.7 | Free Androgen Index (%) −27.2 ± 9.2 | <0.05 | |
| Fasting glucose (mmol/L) 1.2 ± 8.6 | Fasting glucose (mmol/L) 0.4 ± 4.1 | NS | |
| Fasting insulin (pmol/L) −13.1 ± 8.6 | Fasting insulin (pmol/L) −23.4 ± 10.0 | <0.05 | |
| Palomba, 2010 [ | Follicle Stimulating Hormone (mIU/mL) 4.9 ± 3.1 | Follicle Stimulating Hormone (mIU/mL) 4.2 ± 1.2 | NS |
| Testosterone (nmol/L) 2.2 ± 0.6 | Testosterone (nmol/L) 2.51 ± 0.9 | <0.05 | |
| Sex Hormone Binding Globule (nmol/L) 25.3 ± 3.2 | Sex Hormone Binding Globule (nmol/L) 17.4 ± 3.1 | <0.05 | |
| Free Androgen Index (%) 10.8 ± 3.5 | Free Androgen Index (%) 11.6 ± 3.7 | <0.05 | |
| Fasting glucose (mmol/L) 4.0 ± 1.7 | Fasting glucose (mmol/L) 4.0 ± 1.5 | NS | |
| Fasting insulin (pmol/L) 15.8 ± 3.9 | Fasting insulin (pmol/L) 17.9 ± 4.2 | <0.05 | |
| Stamets, 2004 [ | Testosterone (ng/dL) −9 ± 21 | Testosterone (ng/dL) −9 ± 18 | 0.96 |
| Luteinizing hormone (mIU/mL) 7 ± 30 | Luteinizing hormone (mIU/mL) 2 ± 11 | 0.59 | |
| Follicle Stimulating Hormone (mIU/mL) −1 ± 5 | Follicle Stimulating Hormone (mIU/mL) 2 ± 4 | 0.12 | |
| Area under Curve Insulin 3 h Oral Glucose Tolerance Test −2912 ± 13,562 | Area Under Curve Insulin 3 h Oral Glucose Tolerance Test −8734 ± 12,218 | 0.26 | |
| Area Under Curve Glucose 3 h Oral Glucose Tolerance Test −87 ± 2803 | Area Under Curve Glucose 3 h Oral Glucose Tolerance Test −93 ± 2049 | 0.99 | |
| Thomson, 2008 [ | Glucose (mmol/L) 4.96 ± 0.6 | Glucose (mmol/L)5.32 ± 0.49 | <0.01 |
| Insulin (mU/L) 13.5 ± 9.9 | Insulin (mU/L) 17.7 ± 8.2 | <0.01 | |
| Testosterone (nmol/L) 2.09 ± 0.98 | Testosterone (nmol/L) 2.36 ± 0.71 | NS | |
| Sex Hormone Binding Globule (nmol/L) 31.5 ± 17.5 | Sex Hormone Binding Globule (nmol/L) 27.4 ± 15.9 | NS | |
| Free Androgen Index (%) 8.4 ± 6.6 | Free Androgen Index (%) 11.2 ± 5.5 | <0.01 | |
| Moran, 2003 [ | Improved menstrual cyclicity 6/14 42% | Improved menstrual cyclicity 5/14 35% | NR |
| Palomba, 2008 [ | Menses frequency (# observed menses/no expected cycles, %) 18/118 15.3% | Menses frequency (# observed menses/no expected cycles, %) 28/107 26.2% | 0.043 |
| Ovulation rate (# ovulatory cycles/# observed cycles, %) 18/119 15.1% | Ovulation rate (# ovulatory cycles/# observed cycles, %) 28/113 24.8% | 0.032 | |
| Palomba, 2010 [ | Ovulation rate 12/32 37.5% | Ovulation rate 3/32 9.4% | 0.020 |
| Thomson, 2008 [ | Improved menstrual cyclicity 3/14 21.4% | Improved menstrual cyclicity 0/14 0% | NR |
| Mavropoulos, 2005 [ | Pregnancy 2/5 40% | Pregnancy 0/5 0% | NR |
| Moran, 2003 [ | Pregnancy (# pregnancies/# patients, %) 2/14 14% | Pregnancy (# pregnancies/# patients, %) 1/14 7% | NR |
| Palomba, 2008 [ | Pregnancy (# pregnancies/# patients, %) 2/20 10% | Pregnancy (# pregnancies/# patients, %) 7/20 35% | 0.058 |
| Sim, 2014 [ | Natural conception 3/27 0.1% | Natural conception 0/22 0% | 0.11 |
| Pregnancy rate 13/27 48.1% | Pregnancy rate 3/22 13.6% | 0.007 | |
NS = not significant; NR = not reported; data extracted by review authors where required from published graphs, # = number.